Recognition highlights Hong Kong's strength
in university research translation and life and health technology industrialisation

HONG KONG, Oct. 20, 2026 /PRNewswire/ -- G–NiiB GenieBiome, a biotechnology spinout from The Chinese University of Hong Kong, has been named one of Hong Kong's inaugural New Industrialisation Elite Enterprises.

Conferred by the Innovation, Technology and Industry Bureau of the Government of the Hong Kong Special Administrative Region, the recognition affirms the company's research capabilities, growth potential, local contribution and impact on Hong Kong's innovation ecosystem.

The inaugural New Industrialisation Elite Enterprises Nurturing Programme attracted more than 100 nominations. Following a rigorous assessment, G–NiiB GenieBiome was selected as one of only eight enterprises in the inaugural cohort. The assessment focused on three core dimensions: research capabilities, growth potential, and local contribution and ecosystem impact.

The programme supports the direction set out in Hong Kong's First Five–Year Plan to advance new industrialisation and accelerate the development of innovation and technology industries. It focuses on supporting high-growth enterprises developing in Hong Kong and contributing to the local economy and employment. The HKSAR Government also intends the recognition label to help selected enterprises build market credibility and enhance market recognition.

Speaking at the award presentation ceremony, Professor Sun Dong, Secretary for Innovation, Technology and Industry, noted that the inaugural cohort includes start-ups emerging from research conducted by Hong Kong universities. He added that the selected enterprises demonstrate the vibrant ecosystem and diversity of Hong Kong's new industrial development.

From CUHK research to industrial and societal impact

G–NiiB GenieBiome is a biotechnology spinout from The Chinese University of Hong Kong, founded by world-renowned clinician-scientists and supported by a multidisciplinary team with expertise spanning microbiology, metagenomics, bioinformatics, disease biomarkers, food technology, clinical research, intellectual property development and commercialisation.

The company specialises in precision microbiome science and is committed to translating Hong Kong research into innovations that address real-world health needs.

G–NiiB GenieBiome's journey connects academic and clinical research at The Chinese University of Hong Kong, microbiome research and translation through the Microbiota I–Center (MagIC), and product development, industrial application and commercialisation through G–NiiB GenieBiome. Together, these capabilities reflect the complete innovation pathway from academic discovery and research translation to market application and societal impact.

Through microbiome-based innovation spanning therapeutics and precision microbiome formulations, G–NiiB GenieBiome transforms world-class science into health solutions with commercial potential and real-world value for individuals, healthcare systems and society.

Creating global value from Hong Kong science

Rachel Fan, Chief Executive Officer of G–NiiB GenieBiome, said: "Being named one of Hong Kong's inaugural New Industrialisation Elite Enterprises represents an important milestone for G–NiiB GenieBiome. This recognition affirms our efforts in scientific innovation, research translation and industrial application. Looking ahead, we will continue to advance microbiome science and transform Hong Kong research into globally relevant health solutions."

Advancing knowledge transfer and industrial innovation

Dr. Kelvin Wong, Director of the Knowledge Transfer Office of The Chinese University of Hong Kong, said: "We warmly congratulate G–NiiB GenieBiome on being named one of Hong Kong's inaugural New Industrialisation Elite Enterprises. This recognition demonstrates how CUHK research can be successfully translated into industrial innovation and societal value, while highlighting the important role of knowledge transfer in advancing Hong Kong's innovation and technology development."

The recognition marks an important milestone in G–NiiB GenieBiome's development. The company will continue to deepen collaboration across research, clinical science, technology and industry, accelerating microbiome research translation, product innovation and industrial application while supporting Hong Kong's position as an international innovation and technology centre.

The honour not only recognises G–NiiB GenieBiome's progress to date, but also underscores the strength and international potential of Hong Kong's research translation and life and health technology sectors.

-End-

About G–NiiB GenieBiome

G–NiiB GenieBiome is a biotechnology spinout from The Chinese University of Hong Kong, founded by world-renowned clinician-scientists and supported by a multidisciplinary team with expertise spanning microbiology, metagenomics, bioinformatics, disease biomarkers, food technology, clinical research, intellectual property development and commercialisation.

For more than a decade, the team has advanced evidence-based microbiome research and applications addressing important health needs across gut health, metabolism, immunity, skin health and mental wellness. Its precision microbiome formulations are developed with the health needs of Asian populations in mind. The company's vision is to transform human health through microbiome innovation.

About the Knowledge Transfer Office of The Chinese University of Hong Kong

The Knowledge Transfer Office (KTO) at The Chinese University of Hong Kong (CUHK) is committed to transforming knowledge and innovation into real-world applications that benefit society. As part of CUHK's strategic focus on engagement and collaboration, KTO connects the University with industry, government and the wider community.

We foster partnerships, support entrepreneurship, and manage intellectual property to drive innovation, contribute to industrial development and deliver solutions that create positive societal impact.